The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a ...

Reclassifying HFmrEF as a stable phenotype aims to reduce therapeutic inertia and GDMT underuse driven by heterogeneous ...

Functional assessment and classification in heart failure encompass a spectrum of tools and frameworks designed to quantify a patient’s symptoms, exercise capacity and underlying cardiac performance.

Cardiosense, a healthcare technology company focused on heart failure care, today announced that the U.S. Food & Drug Administration (FDA) has granted De Novo classification for its PCWP Analysis ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...